Lee Pharmaceuticals (OTCMKTS:LPHM) is a U.S.-based developer and manufacturer of prescription pharmaceuticals, specializing in both generic and branded small-molecule drug products. The company’s core business involves the research, development, and commercialization of oral solid-dose and parenteral formulations across a range of therapeutic areas. Leveraging a proprietary formulation platform, Lee Pharmaceuticals aims to deliver cost-effective alternatives to branded medications while maintaining rigorous quality and compliance standards under U.S. Food and Drug Administration guidelines.
Among the company’s product offerings are generic treatments for gastrointestinal disorders, cardiovascular conditions, pain management and supportive care therapies for oncology patients. In addition to its in-house portfolio, Lee Pharmaceuticals provides contract development and manufacturing organization (CDMO) services, assisting biotech and pharmaceutical partners with formulation optimization, regulatory support and commercial-scale production. This dual model of proprietary product development and fee-for-service manufacturing enables the company to diversify revenue streams and deepen relationships across the healthcare industry.
Founded in 2010 and headquartered in San Diego, California, Lee Pharmaceuticals has since established manufacturing and research facilities in both the United States and India, enhancing global supply chain resilience. Under the leadership of CEO Dr. Michael Lee and a management team drawn from veteran pharmaceutical executives, the company has expanded its footprint with strategic licensing agreements in Latin America and the Asia-Pacific region. Its board includes experts in regulatory affairs, clinical development and global marketing, reflecting a commitment to scientific rigor and market execution.
Looking ahead, Lee Pharmaceuticals continues to advance its late-stage pipeline through ongoing bioequivalence and stability studies, while exploring partnerships to introduce its products into new international markets. By balancing proprietary drug development with CDMO services, the company aims to strengthen its position in the generic arena and capitalize on growing global demand for high-quality, affordable medicines.
AI Generated. May Contain Errors.
